GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Solventum Corp (FRA:KB7) » Definitions » LT-Debt-to-Total-Asset

Solventum (FRA:KB7) LT-Debt-to-Total-Asset : 0.54 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Solventum LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Solventum's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.54.

Solventum's long-term debt to total assets ratio increased from Dec. 2023 (0.00) to Dec. 2024 (0.54). It may suggest that Solventum is progressively becoming more dependent on debt to grow their business.


Solventum LT-Debt-to-Total-Asset Historical Data

The historical data trend for Solventum's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solventum LT-Debt-to-Total-Asset Chart

Solventum Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
- - - - 0.54

Solventum Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - 0.56 0.57 0.53 0.54

Solventum LT-Debt-to-Total-Asset Calculation

Solventum's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )/Total Assets (A: Dec. 2024 )
=7458.55/13806.435
=0.54

Solventum's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=7458.55/13806.435
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Solventum  (FRA:KB7) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Solventum LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Solventum's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Solventum Business Description

Traded in Other Exchanges
Address
2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144
Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.

Solventum Headlines

No Headlines